Online citations, reference lists, and bibliographies.
← Back to Search

Outcome And Prognostic Factors Of Pleural Mesothelioma After Surgical Diagnosis And/or Pleurodesis.

M. Baud, Salvatore Strano, A. Dechartres, Rami Jouni, F. Triponez, C. Chouaid, P. Forgez, D. Damotte, N. Roche, J. Régnard, M. Alifano
Published 2013 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
OBJECTIVE The objective of this study was to evaluate long-term survival and prognostic factors in patients with malignant pleural mesothelioma. METHODS All consecutive patients referred for surgical diagnosis and/or pleurodesis for malignant pleural mesothelioma between 2000 and 2010 were studied. The following parameters were prospectively recorded: age, sex, tobacco consumption, asbestos exposure, type and duration of symptoms, American Society of Anesthesiologists (ASA) score, body mass index, preoperative C-reactive protein levels, white blood cells and platelet count, pachypleuritis on chest radiograph, type of diagnostic surgical procedure, histologic type, modality of pleurodesis, and chemotherapy. Survival was assessed on March 1, 2011. RESULTS A total of 170 patients were included. For the entire population, median survival was 12 months (95% confidence interval [CI], 10-15). Two-, 5-, and 7-year overall survival was 26% (95% CI, 19-35), 11% (95% CI, 6-21), and 5% (95% CI, 9-22), respectively. Asbestos exposure, age, ASA class III versus ASA classes I and II, nonepithelioid histology, C-reactive protein levels >3 mg/L, and white cell count >12,000/mm(3) influenced outcome in univariate analysis. Multivariate analysis showed that nonepithelioid histology (hazard ratio [HR], 2.76; 95% CI, 1.50-5.08); age (HR, 1.05; 95% CI, 1.01-1.08); C-reactive protein levels between 4 and 50 mg/L, and >51 (HR, 2.28; 95% CI, 1.18-4.42; and HR, 2.69; CI, 1.29-5.60, respectively); and leukocytosis >12,000/mm(3) (HR, 2.28; 95% CI, 1.22-4.25) were independent worse survival predictors. CONCLUSIONS Median survival in an unselected population of patients with malignant pleural mesothelioma treated nonsurgically is 12 months. Nonepithelioid histology, older age, abnormal C-reactive protein levels, and leukocytosis are independent predictors of worse survival.
This paper references
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.1097/JTO.0b013e31819578c8
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy
A. Koch (2009)
10.1016/j.jtcvs.2008.12.045
Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors.
T. Yan (2009)
10.1016/J.LUNGCAN.2007.02.004
Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results.
F. Rea (2007)
10.1016/J.ATHORACSUR.2007.06.066
Malignant pleural mesothelioma: surgical management in 285 patients.
P. Schipper (2008)
10.1002/ijc.26229
Pleural malignant mesothelioma epidemic: Incidence, modalities of asbestos exposure and occupations involved from the Italian National Register
A. Marinaccio (2012)
10.1200/JCO.1998.16.1.145
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
Preoperative serum C-reactive protein level in non-small cell lung cancer.
M. Hara (2007)
10.1080/10408440903044928
Time trend of mesothelioma incidence in the United States and projection of future cases: An update based on SEER data for 1973 through 2005
B. Price (2009)
10.1016/j.jtcvs.2009.02.046
Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study.
T. R. Tilleman (2009)
10.1043/1543-2165-133.8.1317
Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.
A. Husain (2009)
10.1183/09031936.00039510
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial
P. V. Van Schil (2010)
10.1097/JTO.0b013e3181ae25bf
Outcome for Patients with Malignant Pleural Mesothelioma Referred for Trimodality Therapy in Western Australia
A. Hasani (2009)
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
10.1159/000321370
A Clinical, Radiographic and Laboratory Evaluation of Prognostic Factors in 363 Patients with Malignant Pleural Mesothelioma
A. C. Tanrıkulu (2010)
10.1002/ijc.23874
Survival of pleural malignant mesothelioma in Italy: A population‐based study
F. Montanaro (2009)
10.1007/978-3-642-10862-4_2
Epidemiology of mesothelioma and historical background.
J. Craighead (2011)
10.1016/j.lungcan.2011.06.007
The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine.
S. Kao (2012)
10.1016/S1556-0864(15)31583-5
Induction Chemotherapy, Extrapleural Pneumonectomy, and Postoperative High-Dose Radiotherapy for Locally Advanced Malignant Pleural Mesothelioma: A Phase II Trial
R. Flores (2006)
10.1172/JCI18921
C-reactive protein: a critical update.
M. Pepys (2003)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1016/j.molmed.2010.01.003
Chemokines and chemokine receptors: new insights into cancer-related inflammation.
G. Lazennec (2010)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
The role of immunohistochemistry in the diagnosis of malignant mesothelioma.
C. Moran (2000)
10.1016/j.jtcvs.2011.07.021
Preresection serum C-reactive protein measurement and survival among patients with resectable non-small cell lung cancer.
M. Alifano (2011)
10.5694/mja11.10125
Increasing incidence of malignant mesothelioma after exposure to asbestos during home maintenance and renovation
Nola J. Olsen (2011)



This paper is referenced by
10.1093/ejcts/ezy258
ERS/EACTS statement on the management of malignant pleural effusions
A. Bibby (2019)
10.21037/tlcr.2020.01.08
Surgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma.
G. Woodard (2020)
10.1016/j.athoracsur.2018.07.081
Is There a Role for Cancer-Directed Surgery in Early-Stage Sarcomatoid or Biphasic Mesothelioma?
S. Kim (2019)
10.2147/LCTT.S102113
Clinical staging of malignant pleural mesothelioma: current perspectives
M. Bonomi (2017)
10.1016/j.jtcvs.2013.04.045
The dog didn't bark.
V. Acton (2013)
10.1038/modpathol.2015.87
Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology
J. Andrici (2015)
10.1097/JTO.0000000000000181
Supplementary Prognostic Variables for Pleural Mesothelioma
H. Pass (2014)
10.1016/j.athoracsur.2015.04.087
Prognostic Score of Long-Term Survival After Surgery for Malignant Pleural Mesothelioma: A Multicenter Analysis.
G. Leuzzi (2015)
10.1016/j.pneumo.2018.09.006
[Malignant pleural mesothelioma: The role of surgery].
L. Fournel (2018)
10.1093/jjco/hyu134
Should we continue to offer extrapleural pneumonectomy to selected mesothelioma patients? A single center experience comparing surgical and non-surgical management.
M. Baud (2014)
10.1016/j.jtcvs.2013.05.021
Reply to the editor.
M. Baud (2013)
10.1183/13993003.00349-2018
ERS/EACTS statement on the management of malignant pleural effusions
A. Bibby (2018)
10.1136/bmjresp-2017-000240
Survival prediction in mesothelioma using a scalable Lasso regression model: instructions for use and initial performance using clinical predictors
A. Kidd (2018)
10.1016/j.athoracsur.2014.11.050
Persistent lung expansion after pleural talc poudrage in non-surgically resected malignant pleural mesothelioma.
O. Rena (2015)
10.1002/cam4.1378
Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis
C. Chouaid (2018)
10.1016/j.jmoldx.2016.07.011
Validation of a Gene Expression Test for Mesothelioma Prognosis in Formalin-Fixed Paraffin-Embedded Tissues.
A. De Rienzo (2017)
10.1007/s12254-014-0166-4
A critical update on prognostic and predictive biomarkers in malignant pleural mesothelioma
B. Ghanim (2014)
Semantic Scholar Logo Some data provided by SemanticScholar